Trial Profile

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1 (Everolimus)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Everolimus (Primary)
Indications Renal cancer
Focus Biomarker; Therapeutic Use

Most Recent Events

08 Jun 2010 Study details were reported at ASCO 2010.
02 Sep 2009 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.
02 Sep 2009 Actual initiation date (Aug 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com